急诊脓毒症患者早期筛查生物标志物的研究现状与展望

陈正钢; 刘励军

doi:10.13201/j.issn.1009-5918.2023.02.010

急诊脓毒症患者早期筛查生物标志物的研究现状与展望

陈正钢¹,
刘励军^2,Δ, ,

- 1.
  上海交通大学医学院苏州九龙医院急诊医学科(江苏苏州，215028)
- 2.
  苏州大学附属第二医院急重症医学科

详细信息

通讯作者: 刘励军，E-mail：liulijun@suda.edu.cn

^Δ审校者

中图分类号: R631

收稿日期: 2022-09-30

刊出日期: 2023-02-10

Progress in and prospect of the research on biomarkers early screening emergency patients for sepsis

CHEN Zhenggang¹,
LIU Lijun^2,Δ, ,

- 1.
  Department of Emergency, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, Suzhou, Jiangsu, 215028, China
- 2.
  Department of Emergency and Intensive Care, the Second Affiliated Hospital of Soochow University

More Information

Corresponding author: LIU Lijun, E-mail: liulijun@suda.edu.cn

Received Date: 30 September 2022

Publish Date: 10 February 2023

摘要

摘要: 脓毒症是一种源于感染，以炎症反应和免疫功能紊乱为演变特征，表现为多脏器功能障碍且具有高度异质性的综合征。脓毒症生物标志物是指病原微生物侵入机体后，在生理、生化、免疫和遗传等方面表达出可测量的指标，用于定量评估机体防御反应状态和病理生理过程，并可用于早期筛查急诊脓毒症患者。新型生物标志物表现出良好的诊断潜力，可能是早期诊断脓毒症患者的突破点。不同类型生物标志物的动态监测和联合评估，可能是脓毒症患者早期筛查的重要举措；另外，生物标志物的床旁即时检验技术为急诊早期筛查脓毒症提供了一种快速、高效、便捷的检测方法。本文阐述了数种不同类型生物标志物早期筛查急诊脓毒症患者的研究现状，以期为构建急诊脓毒症患者早期筛查模型提供依据，从而能更早、更快、更准确地筛查急诊脓毒症患者。
- 脓毒症 /
- 生物标志物 /
- 急诊科 /
- 早期筛查 /
- 即时检验
Abstract: Sepsis is a highly heterogeneous syndrome caused by infection, presenting with multiple organ dysfunction, and is characterized by inflammation and immune dysfunction. Sepsis biomarkers refer to measurable indicators expressed in physiological, biochemical, immune or genetic reactions after infection, which can be used to quantitatively evaluate the state of defense response and pathophysiologic process of the body and to screen emergency patients early for sepsis. New biomarkers have shown good potential for the diagnosis of sepsis, and may be a promising screening way of early detecting emergency patients with sepsis. Repeated testing and dynamic monitoring of different types of biomarkers are one of the important measures to detect patients with sepsis early. Point-of-care testing has proven to be a rapid, efficient and convenient method for the early diagnosis of sepsis in emergency patients. In this paper, the characteristics of several different types of biomarkers are reviewed, which provides a basis for building a model for early screening of sepsis emergency patients and for screening spesis emergency patients earlier, faster and more accurately.
- sepsis /
- biomarkers /
- emergency department /
- early screening /
- point-of-care testing

HTML全文

参考文献(41)

[1]	Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study[J]. Lancet, 2020, 395(10219): 200-211. doi: 10.1016/S0140-6736(19)32989-7
[2]	黄昆鹏, 张进祥. 脓毒症的定义、诊断与早期干预——不可分割的三要素[J]. 临床急诊杂志, 2021, 22(3): 221-226. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZLC202103016.htm
[3]	Wagenlehner FME, Dittmar F. Re: surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021[J]. Eur Urol, 2022, 81(2): 213. doi: 10.1016/j.eururo.2021.11.014
[4]	中国医疗保健国际交流促进会急诊医学分会, 中华医学会急诊医学分会, 中国医师协会急诊医师分会, 等. 中国脓毒症早期预防与阻断急诊专家共识[J]. 临床急诊杂志, 2020, 21(7): 517-529. doi: 10.13201/j.issn.1009-5918.2020.07.001
[5]	Barichello T, Generoso JS, Singer M, et al. Biomarkers for sepsis: more than just fever and leukocytosis-a narrative review[J]. Crit Care, 2022, 26(1): 14. doi: 10.1186/s13054-021-03862-5
[6]	Garvik OS, Póvoa P, Magnussen B, et al. C-reactive protein and albumin kinetics before community-acquired bloodstream infections-a Danish population-based cohort study[J]. Epidemiol Infect, 2020, 148: e38. doi: 10.1017/S0950268820000291
[7]	Póvoa P, Martin-Loeches I, Ramirez P, et al. Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study[J]. Ann Intensive Care, 2016, 6(1): 32. doi: 10.1186/s13613-016-0134-8
[8]	唐瑜, 吕健, 张丽茹, 等. 脓毒症早期识别的研究进展[J]. 临床急诊杂志, 2022, 23(7): 513-518. doi: 10.13201/j.issn.1009-5918.2022.07.011 https://lcjz.whuhzzs.com/article/doi/10.13201/j.issn.1009-5918.2022.07.011
[9]	Stocker M, van Herk W, El Helou S, et al. C-reactive protein, procalcitonin, and white blood count to rule out neonatal early-onset sepsis within 36 hours: a secondary analysis of the neonatal procalcitonin intervention study[J]. Clin Infect Dis, 2021, 73(2): e383-e390. doi: 10.1093/cid/ciaa876
[10]	Koizumi Y, Sakanashi D, Ohno T, et al. Plasma procalcitonin levels remain low at the onset of gram-positive bacteremia regardless of severity or the presence of shock: a retrospective analysis of patients with detailed clinical characteristics[J]. J Microbiol Immunol Infect, 2021, 54(6): 1028-1037. doi: 10.1016/j.jmii.2020.08.015
[11]	Huang EQ, Huang DZ, Wang Y, et al. Active droplet-array microfluidics-based chemiluminescence immunoassay for point-of-care detection of procalcitonin[J]. Biosens Bioelectron, 2022, 195(1): 113684.
[12]	Graf R. Pancreatic stone protein-sepsis and the riddles of the exocrine pancreas[J]. Pancreatology, 2020, 20(3): 301-304. doi: 10.1016/j.pan.2020.01.016
[13]	Prazak J, Irincheeva I, Llewelyn MJ, et al. Accuracy of pancreatic stone protein for the diagnosis of infection in hospitalized adults: a systematic review and individual patient level meta-analysis[J]. Crit Care, 2021, 25(1): 182-192. doi: 10.1186/s13054-021-03609-2
[14]	Pugin J, Daix T, Pagani JL, et al. Serial measurement of pancreatic stone protein for the early detection of sepsis in intensive care unit patients: a prospective multicentric study[J]. Crit Care, 2021, 25(1): 151-160. doi: 10.1186/s13054-021-03576-8
[15]	Niggemann P, Rittirsch D, Buehler PK, et al. Incidence and time point of sepsis detection as related to different sepsis definitions in severely burned patients and their accompanying time course of pro-inflammatory biomarkers[J]. J Pers Med, 2021, 11(8): 701-713. doi: 10.3390/jpm11080701
[16]	Putallaz L, Bogaard Pvan den, Laub P, et al. Nanofluidics drives point-of-care technology for on the spot protein marker analysis with rapid actionable results[J]. J Nanomed Nanotechnol, 2019, 10(5): 536-542.
[17]	Lu B, Zhang Y, Li C, et al. The utility of presepsin in diagnosis and risk stratification for the emergency patients with sepsis[J]. Am J Emerg Med, 2018, 36(8): 1341-1345. doi: 10.1016/j.ajem.2017.12.038
[18]	Ruan L, Chen GY, Liu Z, et al. The combination of procalcitonin and C-reactive protein or presepsin alone improves the accuracy of diagnosis of neonatal sepsis: a meta-analysis and systematic review[J]. Crit Care, 2018, 22(1): 316-325. doi: 10.1186/s13054-018-2236-1
[19]	Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin(sCD14-ST)[J]. Clin Chimica Acta, 2011, 412(23-24): 2157-2161. doi: 10.1016/j.cca.2011.07.024
[20]	Mahmoodpoor A, Movassaghpour A, Talebi M, et al. Value of flow cytometry(HLA-DR, CD14, CD25, CD13, CD64) in prediction of prognosis in critically ill septic patients admitted to ICU: a pilot study[J]. J Clin Anesth, 2020, 61: 109646-109648. doi: 10.1016/j.jclinane.2019.109646
[21]	Yeh CF, Wu CC, Liu SH, et al. Comparison of the accuracy of neutrophil CD64, procalcitonin, and C-reactive protein for sepsis identification: a systematic review and meta-analysis[J]. Ann Intensive Care, 2019, 9(1): 5-17. doi: 10.1186/s13613-018-0479-2
[22]	Hassan U, Ghonge T, Reddy B Jr, et al. A point-of-care microfluidic biochip for quantification of CD64 expression from whole blood for sepsis stratification[J]. Nat Commun, 2017, 8(7): 15949-15961.
[23]	Urrechaga E, Bóveda O, Aguirre U. Improvement in detecting sepsis using leukocyte cell population data(CPD)[J]. Clin Chem Lab Med, 2019, 57(6): 918-926. doi: 10.1515/cclm-2018-0979
[24]	Agnello L, Lo Sasso B, Bivona G, et al. Reference interval of monocyte distribution width(MDW)in healthy blood donors[J]. Clin Chimica Acta, 2020, 510: 272-277. doi: 10.1016/j.cca.2020.07.036
[25]	Crouser ED, Parrillo JE, Seymour C, et al. Improved early detection of sepsis in the ED with a novel monocyte distribution width biomarker[J]. Chest, 2017, 152(3): 518-526. doi: 10.1016/j.chest.2017.05.039
[26]	Agnello L, Vidali M, Lo Sasso B, et al. Monocyte distribution width(MDW)as a screening tool for early detecting sepsis: a systematic review and meta-analysis[J]. Clin Chem Lab Med, 2022, 60(5): 786-792. doi: 10.1515/cclm-2021-1331
[27]	Hausfater P, Boter NR, Indiano CM, et al. Monocyte distribution width(MDW)performance as an early sepsis indicator in the emergency department: comparison with CRP and procalcitonin in a multicenter international European prospective study[J]. Crit Care, 2021, 25(1): 227-239. doi: 10.1186/s13054-021-03622-5
[28]	Crouser ED, Parrillo JE, Seymour CW, et al. Monocyte distribution width: a novel indicator of sepsis-2 and sepsis-3 in high-risk emergency department patients[J]. Crit Care Med, 2019, 47(8): 1018-1025. doi: 10.1097/CCM.0000000000003799
[29]	Agnello L, Lo Sasso B, Vidali M, et al. Validation of monocyte distribution width decisional cutoff for sepsis detection in the acute setting[J]. Int J Lab Hematol, 2021, 43(4): O183-O185.
[30]	Buoro S, Manenti B, Seghezzi M, et al. Innovative haematological parameters for early diagnosis of sepsis in adult patients admitted in intensive care unit[J]. J Clin Pathol, 2018, 71(4): 330-335. doi: 10.1136/jclinpath-2017-204643
[31]	Tauseef A, Zafar M, Arshad W, et al. Role of immature platelet fraction(IPF)in sepsis patients: a systematic review[J]. J Family Med Prim Care, 2021, 10(6): 2148-2152. doi: 10.4103/jfmpc.jfmpc_2293_20
[32]	王宗培, 谢智慧, 赵玉洁, 等. 共刺激分子程序性细胞死亡受体-1/程序性细胞死亡受体配体-1调控树突状细胞对脓毒症患者免疫功能的影响[J]. 中华危重病急救医学, 2021, 33(9): 1032-1039. doi: 10.3760/cma.j.cn121430-20210419-00572
[33]	Qin WT, Hu LP, Zhang XL, et al. The diverse function of PD-1/PD-L pathway beyond cancer[J]. Front Immunol, 2019, 10: 2298-2314. doi: 10.3389/fimmu.2019.02298
[34]	Meghraoui-Kheddar A, Chousterman BG, Guillou N, et al. Two new neutrophil subsets define a discriminating sepsis signature[J]. Am J Respir Crit Care Med, 2022, 205(1): 46-59. doi: 10.1164/rccm.202104-1027OC
[35]	Yadav P, Trehanpati N, Maiwall R, et al. Soluble factors and suppressive monocytes can predict early development of sepsis in acute-on-chronic liver failure[J]. Hepatol Commun, 2022, 6(8): 2105-2120. doi: 10.1002/hep4.1949
[36]	Xing Y, Liu JT, Luo JP, et al. A dual-channel intelligent point-of-care testing system for soluble programmed death-1 and programmed death-ligand 1 detection based on folding paper-based immunosensors[J]. ACS Sens, 2022, 7(2): 584-592. doi: 10.1021/acssensors.1c02486
[37]	Miller RR 3rd, Lopansri BK, Burke JP, et al. Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating sepsis from Systemic Inflammatory Response Syndrome in the ICU[J]. Am J Respir Crit Care Med, 2018, 198(7): 903-913. doi: 10.1164/rccm.201712-2472OC
[38]	Sampson D, Yager TD, Fox B, et al. Blood transcriptomic discrimination of bacterial and viral infections in the emergency department: a multi-cohort observational validation study[J]. BMC Med, 2020, 18(1): 185-197. doi: 10.1186/s12916-020-01653-3
[39]	Ducharme J, Self WH, Osborn TM, et al. A multi-mRNA host-response molecular blood test for the diagnosis and prognosis of acute infections and sepsis: proceedings from a clinical advisory panel[J]. J Pers Med, 2020, 10(4): 266-286. doi: 10.3390/jpm10040266
[40]	Safarika A, Wacker JW, Katsaros K, et al. A 29-mRNA host response test from blood accurately distinguishes bacterial and viral infections among emergency department patients[J]. Intensive Care Med Exp, 2021, 9(1): 31-47. doi: 10.1186/s40635-021-00394-8
[41]	Schneider JE, Romanowsky J, Schuetz P, et al. Cost impact model of a novel multi-mRNA host response assay for diagnosis and risk assessment of acute respiratory tract infections and sepsis in the emergency department[J]. J Health Econ Outcomes Res, 2020, 7(1): 24-34. doi: 10.36469/jheor.2020.12637